What are the indications for capmatinib?

Capmatinib (Capmatinib), as a highly efficient and selective MET inhibitor, its core indication is targeted at carrying MET Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with skipping mutations in pan>Exon14. This type of specific gene mutation will lead to abnormal activation of the MET signaling pathway, thereby driving the crazy growth and spread of tumor cells. Capmatinib effectively inhibits the proliferation of tumor cells by precisely inhibiting the MET pathway, and has demonstrated impressive objective response rates (ORR) in multiple clinical trials.

With the authoritative approval of the U.S. Food and Drug Administration (FDA), capmatinib is not only suitable for patients who have not received other treatments, but also brings new hope to those patients who still retain MET exon 14 skipping mutations after failure of other treatments. Whether used as first-line treatment or later-line treatment, the efficacy of capmatinib has been fully verified in clinical studies.

It is worth mentioning that although capmatinib is currently mainly used for MET exon 14 skipping mutations, studies have also revealed that it may be equally effective in patients with tumors with MET gene amplification or overexpression. Especially in some METamplified NSCLC patients, capmatinib has initially shown therapeutic potential, but the expansion of this indication requires more research and the green light from regulatory agencies.

In addition, capmatinib also shows great promise in joining forces with other targeted drugs. For example, combined use with EGFR inhibitors provides a new treatment strategy for patients with EGFR mutations and MET amplification. This combination therapy is expected to open up new treatment paths for patients who are resistant to single targeted drugs, and related research is in full swing.

In addition to the field of lung cancer, METexon14 mutations and MET amplification have also been found in various solid tumors such as gastric cancer, liver cancer, and glioblastoma. Although the efficacy of capmatinib in these cancers has yet to be fully proven, preliminary studies have revealed positive signals that it may also have therapeutic value in other tumor types with abnormal MET.

xa0

Reference materials

FDA Capmatinib Approval Information -

https://www.fda.gov/drugs/drug-approvals-and-databases/tabrecta-capmatinib